Life Span Enhancing Prescriptions: Promise, Pitfalls, and Practical Pathways

Introduction

The idea that aging itself might be modifiable is no longer confined to science fiction. A growing field known as geroscience has identified multiple biological pathways (Figure 1) that appear to drive aging and age-related disease [1,2]. Drugs that target these pathways are often referred to as gerotherapeutics.
Once purely experimental, gerotherapeutics are now “coming of age.” Several existing medications originally developed for diabetes, osteoporosis, or transplantation, have been shown to either extend lifespan or improve healthspan in animal models and, in some cases, human observational studies [3,4]. While these therapies are not formally approved for “aging,” they are already being accessed by a small but growing group of individuals through specialized longevity clinics [5].
This raises an important question: Can the average patient access these therapies through their primary care physician—and should they? This article explores the science, the ethical and legal landscape, and the practical realities of lifespan-enhancing prescriptions.

Figure 1. Twelve hallmarks of the aging process proposed by López-Otín, C. et al. [1]

Commonly Discussed Gerotherapeutics
 
All were originally FDA-approved for specific metabolic or immune conditions but were not designed to extend lifespan. Their gerotherapeutic potential emerged through:

• Animal studies demonstrating lifespan extension
• Epidemiological observations showing reduced mortality
• Mechanistic insights linking drug targets to aging pathways

This convergence of evidence has led researchers to consider them as candidates for targeting aging itself. The following discussion will consider 6 key classes of gerotherapeutics:

• Metformin
• Rapamycin (Sirolimus)
• Acarbose
• SGLT2 Inhibitors (e.g., Empagliflozin, Canagliflozin)
• GLP-1 Receptor Agonists (e.g., Semaglutide, Tirzepatide)
• Bisphosphonates (e.g. Alendronate, Zoledronate)

They all scored 9 points or better out of 12, based on the ranking scheme developed by Leone, M. & Barzilai, N. [3]. The scheme assigned points according to available preclinical and clinical evidence, including rodent lifespan and healthspan, hallmarks of aging, human mortality and health span. Details about their original FDA-approved indications, relevance to geroscience, and evidence for classification as geretherapeutics, can be found in the Appendix.

Legal and Ethical Considerations
 
Patients and their primary care physician (PCP) will essentially have to walk the tightrope in this area since the path to a longevity prescription is paved with complex legal and ethical questions. Legally, once a drug is FDA-approved for one condition, a doctor can prescribe it for another. However, because "aging" is not currently recognized as a disease by the FDA, any prescription for the sole purpose of life extension is considered off-label. While legal, this often means insurance will not cover the cost, and the doctor assumes a higher degree of professional liability if side effects occur in a "healthy" patient.
In addition, legality does not guarantee ethical appropriateness. Prescribing gerotherapeutics to otherwise healthy individuals raises at least four ethical concerns:
 
1. Evidence Gap
While animal data are compelling, definitive human trials demonstrating lifespan extension are still lacking. The proposed TAME (Targeting Aging with Metformin) trial aims to address this gap [17].
 
2. Risk vs. Benefit
All medications carry risks:

• Metformin: gastrointestinal effects, vitamin B12 deficiency
• Rapamycin: immunosuppression, lipid abnormalities
• SGLT2 inhibitors: infections, rare ketoacidosis
• GLP-1 agonists: gastrointestinal symptoms
• Bisphosphonates: rare, atypical fractures, osteonecrosis of the jaw

In healthy individuals, even small risks may outweigh uncertain benefits.
 
3. Professional Guidelines
Medical organizations emphasize:

• Evidence-based practice
• Patient safety
• Clear therapeutic intent

Since aging is not classified as a disease, prescribing purely for lifespan extension falls outside standard care.
 
4. Equity and Access
Longevity therapies are currently more accessible to affluent individuals, raising concerns about widening health disparities.
 
Considering the above, most physicians will not feel ethically compelled to prescribe gerotherapeutics to perfectly healthy individuals seeking life span extension. However, in this age of advanced molecular diagnostics and imaging, and affordable whole genome sequencing, how many could claim perfect health? Perhaps very few, while most might exhibit borderline conditions that could benefit from early interventions with gerotherapeutics within legal and ethical boundaries.

​The "Borderline" Path to Access

The most ethically and clinically defensible pathway is not treating “aging,” but addressing early or borderline disease states. For the average person, the most viable way to access these drugs is through co-morbidity management. A primary care doctor is far more likely to prescribe a gerotherapeutic if the patient also has a "borderline" medical condition where the drug provides an immediate, approved clinical benefit. In other words, a prescription becomes more justifiable when:

• There is measurable physiological deviation
• The drug has proven benefit in related conditions
• The goal is risk reduction, not enhancement

 
The following are examples of strategic clinical entry points to gerotherapeutics. If you already know you have one or more of the following risk factors or borderline conditions, the table below may be directly relevant to a conversation with your doctor. If you're currently healthy with no known risk factors, a brief scan is sufficient — the closing summary table offers the clearest overview.
 
1. Prediabetes / Insulin Resistance Spectrum
Relevant drug: Metformin, Acarbose
This is probably the strongest and most widely accepted gray-zone indication.
Clinical scenarios:

• HbA1c: 5.7–6.4%
• Elevated fasting insulin
• History of gestational diabetes
• Visceral adiposity with normal glucose

Why it’s defensible:

• American Diabetes Association (ADA) guidelines already allow metformin in high-risk prediabetes
• Diabetes Prevention Program (DPP) supports risk reduction
• Acarbose has evidence for delaying diabetes onset

Here, “longevity” becomes secondary to metabolic risk modification
 
2. Early Cardiometabolic Syndrome (Even Without Diabetes)
Relevant drug: SGLT2 inhibitors
Clinical scenarios:

• Central obesity + mild hypertension + dyslipidemia
• Elevated triglyceride/HDL ratio
• Early fatty liver

Why it’s defensible:

• SGLT2 inhibitors have cardio-renal protective effects independent of glucose
• Trials show benefit even in non-diabetics (e.g., heart failure populations)

This is shifting toward organ protection rather than glucose control
 
3. Stage 1 Chronic Kidney Disease (CKD) or Hyperfiltration
Relevant drug: SGLT2 inhibitors
Clinical scenarios:

• Estimated glomerular filtration rate (eGFR) still “normal” but declining
• Microalbuminuria
• Hyperfiltration (common in early metabolic disease)

Why it’s defensible:

• Strong evidence from randomly controlled trials (RCT) for renal protection—even in non-diabetics
• Increasingly used earlier in disease progression

This is one of the most medically accepted “early intervention” uses today
 
4. Early Heart Failure Risk / Subclinical Cardiac Dysfunction
Relevant drug: SGLT2 inhibitors
Clinical scenarios:

• Diastolic dysfunction
• Elevated B-type natriuretic peptide (BNP) but no overt heart failure
• Long-standing hypertension with left ventricular hypertrophy

Why it’s defensible:

• SGLT2 inhibitors reduce hospitalization and mortality in HF (including non-diabetics)
• Cardiologists are increasingly prescribing them earlier

Again, reframed as cardioprotection, not longevity
 
5. Post-Transplant or Immune Dysregulation Contexts
Relevant drug: Rapamycin
Clinical scenarios:

• Organ transplant (already standard use)
• Rare immune dysregulation disorders
• Certain dermatologic or oncologic indications (off-label)

Why it’s relevant to gerotherapeutics:

• These patients already receive rapamycin
• Observationally, some show reduced cancer incidence and age-related pathology

Not a justification for healthy individuals—but a natural experiment in humans
 
6. Severe Postprandial Hyperglycemia with Normal Fasting Glucose
Relevant drug: Acarbose
Clinical scenarios:

• Normal HbA1c but large glucose spikes after meals
• Continuous glucose monitoring (CGM) reveals excursions >160–180 mg/dL

Why it’s defensible:

• Postprandial spikes are linked to:
  • Oxidative stress
  • Endothelial dysfunction
• Acarbose specifically targets this mechanism

This is a very “geroscience-aligned” phenotype
 
7. Polycystic Ovary Syndrome (PCOS) with Mild Metabolic Dysfunction
Relevant drug: Metformin
Clinical scenarios:

• Insulin resistance without overt diabetes
• Irregular cycles, hyperandrogenism

Why it’s defensible:

• Metformin is already widely used in PCOS
• Improves insulin sensitivity and metabolic profile

Another case where longevity effects are incidental, not primary
 
8. Non-Alcoholic Fatty Liver Disease
Relevant drugs:

• Metformin (limited effect)
• SGLT2 inhibitors (more promising)

Clinical scenarios:

• Elevated ALT/AST
• Imaging-confirmed fatty liver

Why it’s defensible:

• Strong overlap with metabolic aging pathways
• SGLT2 inhibitors show improvements in liver fat

 
9. Obesity with Early Metabolic Drift (But No Disease Yet)
Relevant drugs:

• Metformin
• SGLT2 inhibitors

Clinical scenarios:

• BMI >30 with subtle lab abnormalities
• Rising fasting insulin, borderline lipids

Why it’s defensible:

• Obesity itself is increasingly treated as a disease
• These drugs may reduce downstream risk

 
10. Osteopenia (Not Yet Osteoporosis)
Relevant drug: Bisphosphonates
Clinical scenario:

• T-score: −1.0 to −2.5 (osteopenia)
• No fragility fractures yet
• Possibly additional risk factors (age, steroid exposure, family history)

Why this is a strong borderline case:

• Many guidelines already allow treatment if fracture risk (e.g., FRAX) is elevated
• Observational data suggests bisphosphonates may:
  • Reduce mortality
  • Affect systemic aging processes (possibly via bone–immune signaling)

This is one of the cleanest “pre-disease → intervention” pathways in medicine
 
11. “Normal Weight” but High Visceral Adiposity
Relevant drug: GLP-1 receptor agonists
Clinical scenario:

• Body Mass Index (BMI) in normal or slightly overweight range
• High visceral fat (waist circumference, imaging)
• Early insulin resistance or dyslipidemia

Why it’s defensible:

• GLP-1 agonists improve:
  • Insulin sensitivity
  • Weight distribution
  • Inflammation markers
• Cardiovascular outcome trials show benefit beyond glucose lowering

This reframes treatment as metabolic risk reduction, not cosmetic weight loss
 
12. “Pre-Frailty” or Early Functional Decline
Relevant drug: Bisphosphonates
Clinical scenario:

• Mild sarcopenia
• Slower gait speed
• Reduced grip strength
• No fractures yet

Why it is interesting:

• Bone and muscle aging are tightly linked
• Preventing micro-fractures and bone turnover may:
  • Preserve mobility
  • Reduce downstream morbidity

This is very aligned with geroscience, though still emerging and debated
 
13. Obesity (Now Explicitly a Disease)
Relevant drugs:

• GLP-1 receptor agonists
• (also overlaps with metformin and SGLT2i)

Clinical scenario:

• Body Mass Index (BMI) ≥30 (or ≥27 with comorbidities)

Why this is no longer really “borderline”:

• Obesity is now widely recognized as a chronic disease
• GLP-1 agonists (e.g., semaglutide class) are FDA-approved for weight management

Why it matters for gerotherapeutics:

• These drugs:
  • Reduce cardiovascular events
  • Improve Metabolic Health
  • Likely influence aging pathways (inflammation, nutrient sensing)

This is currently the most socially accepted “longevity-adjacent” prescribing
 
14. Early Atherosclerotic Risk Without Overt Disease
Relevant drugs:

• GLP-1 receptor agonists
• SGLT2 inhibitors

Clinical scenario:

• Elevated coronary artery calcium (CAC)
• Borderline lipid abnormalities
• Family history of premature cardiovascular disease (CVD)

Why it’s defensible:

• GLP-1 agonists reduce major adverse cardiovascular events
• Effects extend beyond glycemic control

This becomes vascular aging prevention, not just diabetes care
 
15. Weight Regain After Lifestyle Intervention
Relevant drug: GLP-1 receptor agonists
Clinical scenario:

• Patient successfully loses weight
• Then begins regaining despite adherence

Why it’s defensible:

• Obesity is increasingly treated as a relapsing neuroendocrine condition
• GLP-1 agents help maintain weight loss

Ethically framed as chronic disease management, not enhancement
 
16. High Bone Turnover Without Low bone mineral density (BMD) Yet
Relevant drug: Bisphosphonates
Clinical scenario:

• Normal BMD but elevated bone turnover markers
• Perimenopausal or early postmenopausal state

Why it’s a gray zone:

• Not standard practice yet
• But mechanistically:
  • High turnover → microarchitectural decline → future fracture risk

A forward-looking, risk-based approach, but still controversial
 
17. Metabolic Syndrome with Inflammatory Phenotype
Relevant drugs:

• GLP-1 receptor agonists
• Metformin

Clinical scenario:

• Elevated CRP
• Central obesity, in this context may not be clinically obvious and can occur in individuals with a normal BMI, making this phenotype easy to overlook
• Borderline glucose and lipids

Why it’s compelling:

• GLP-1 agonists reduce systemic inflammation
• Inflammation is a core aging pathway

 
18. High-Normal Uric Acid (Hyperuricemia)
Relevant Drug:

• SGLT2 Inhibitors

Clinical scenario:

• Borderline high blood pressure
• Elevated uric acid levels (a risk for gout and kidney stones).

Why it’s compelling:

• SGLT2i's are "calorie restriction mimetics"
• SGLT2i's have a side effect of lowering serum uric acid
• They are increasingly used in cardiology and nephrology for "organ protection" rather than just glucose management.

 
19. Chronic "Inflammaging" (High-Sensitivity C-reactive protein (hs-CRP))
Relevant Drug:

• Low-Dose Rapamycin

Clinical scenario:

• High hs-CRP (a marker of systemic inflammation)
• No specific autoimmune disease.

Why it’s compelling:

• Rapamycin is immunosuppressive at standard dose
• Improve immune function in the elderly
• Extend life span in animal model at low dose

This remains the most difficult for a general practitioner to justify. It is usually handled by "Longevity Clinics" that use it to treat the biological process of aging itself, often supported by the 2014 Mannick study showing improved immune response in seniors on low dose rapalogs [18].
 
In summary, the ease of getting a prescription for life span extension varies proportionally with the ethical barrier. The rank order is shown in the following Table for all six classes of gerotherapeutics:

Drug/Class	Ease of ethical justification (healthy/borderline)
GLP-1 agonists	High
SGLT2 inhibitors	High
Metformin	Moderate–high
Bisphosphonates	Moderate (context-dependent)
Acarbose	Moderate
Rapamycin	Low

---

Conclusion

Gerotherapeutics represents a fascinating and rapidly evolving frontier in medicine. They represent a change in thinking about patient management, moving from a "reactive" model (fixing what is broken) to a "proactive" model (slowing the rate of decay). While science suggests that targeting aging biology is possible, clinical practice has not yet fully caught up. For now, these drugs are legally accessible through off-label prescribing although their use purely for longevity remains ethically debated.
 
The most practical pathway towards gerotherapeutics is through existing or early-stage medical conditions. Patients interested in these therapies should engage in informed discussions with their physicians, focusing on individual risk factors rather than abstract longevity goals. As research advances and clinical trials mature, the boundary between prevention and enhancement may continue to blur. Until then, lifespan-enhancing prescriptions remain less about chasing immortality and more about thoughtfully managing the biology of aging as it begins to unfold.
 
The most practical takeaway for an apparently healthy individual is this: don't settle for a cursory annual check-up. A more proactive approach — one that includes a detailed family history, targeted lab work, and relevant imaging — is far more likely to reveal the borderline conditions described above. If risk factors emerge, that becomes the opening for an informed conversation with your doctor about medications that address those risks while also supporting long-term healthspan. The goal isn't to ask for a longevity prescription. It's to ask the right questions about where your biology actually stands.

References

1. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023). Hallmarks of aging: An expanding universe. Cell, 186(2), 243-278. DOI: 10.1016/j.cell.2022.11.001
2. Kulkarni, A. S., Aleksic, S., Berger, D. M., Sierra, F., Kuchel, G. A., & Barzilai, N. (2022). Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization. Aging Cell, 21(4), e13596. https://doi.org/10.1111/acel.13596
3. Leone, M., & Barzilai, N. (2024). An updated prioritization of geroscience-guided FDA-approved drugs repurposed to target aging. Medical Research Archives, 12(2). https://doi.org/10.18103/mra.v12i2.5138
4. Wang, W., Guan, L., Kuerec, A. H., Barzilai, N., & Maier, A. B. (2026). Use of potential gerotherapeutic drugs and mortality in geriatric rehabilitation inpatients: RESORT. Mechanisms of Ageing and Development, 112163. https://doi.org/10.1016/j.mad.2026.112163
5. Demaria, M. (2025). Longevity clinics: between promise and peril. Aging (Albany NY), 17(10), 2452. https://doi.org/10.18632/aging.206330
6. Kulkarni, A. S., Gubbi, S., & Barzilai, N. (2020). Benefits of metformin in attenuating the hallmarks of aging. Cell metabolism, 32(1), 15-30. DOI: 10.1016/j.cmet.2020.04.001 
7. Diabetes Prevention Program Research Group. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England journal of medicine, 346(6), 393-403. DOI: 10.1056/NEJMoa012512
8. Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., ... & Miller, R. A. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. nature, 460(7253), 392-395. https://doi.org/10.1038/nature08221
9. Harrison, D. E., Strong, R., Alavez, S., Astle, C. M., DiGiovanni, J., Fernandez, E., ... & Miller, R. A. (2019). Acarbose improves health and lifespan in aging HET3 mice. Aging cell, 18(2), e12898. https://doi.org/10.1111/acel.12898
10. Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., ... & Sabatine, M. S. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 380(4), 347-357. DOI: 10.1056/NEJMoa1812389
11. Zhang, J., Cai, W., Liu, D., Zheng, N., Wang, Y., Qiu, F., ... & Xu, J. (2025). Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study. Cell Reports Medicine, 6(9). https://doi.org/10.1016/j.xcrm.2025.102331
12. Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. [Updated 2024 Feb 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551568/
13. Hamed, K., Alosaimi, M. N., Ali, B. A., Alghamdi, A., Alkhashi, T., Alkhaldi, S. S., ... & Alhulayfi, H. (2024). Glucagon-like peptide-1 (GLP-1) receptor agonists: exploring their impact on diabetes, obesity, and cardiovascular health through a comprehensive literature review. Cureus, 16(9). doi: 10.7759/cureus.68390
14. Lu, J., Rao, S. R., Knowles, H., Zhan, H., Gamez, B., Platt, E., ... & Edwards, J. R. (2025). Bisphosphonates trigger anti-ageing effects across multiple cell types and protect against senescence. bioRxiv. doi: 10.1101/2025.03.25.645228
15. Slade, L., Bollen, S. E., Bass, J. J., Phillips, B. E., Smith, K., Wilkinson, D. J., ... & Etheridge, T. (2023). Bisphosphonates attenuate age‐related muscle decline in Caenorhabditis elegans. Journal of Cachexia, Sarcopenia and Muscle, 14(6), 2613-2622. doi: 10.1002/jcsm.13335
16. Center, J. R., Lyles, K. W., & Bliuc, D. (2020). Bisphosphonates and lifespan. Bone, 141, 11556.. https://doi.org/10.1016/j.bone.2020.115566
17. American Federation of Aging Research. The TAME Trials: Targeting the biology of aging. Ushering a new era of interventions. Retrieved April 7, 2026 from: https://www.afar.org/tame-trial
18. Mannick, J. B., Del Giudice, G., Lattanzi, M., Valiante, N. M., Praestgaard, J., Huang, B., ... & Klickstein, L. B. (2014). mTOR inhibition improves immune function in the elderly. Science translational medicine, 6(268), 268ra179-268ra179. DOI: 10.1126/scitranslmed.3009892

Appendix

6 classes of gerotherapeutics, their original FDA-approved indications, relevance to geroscience, and evidence as gerotherapeutics.
 
Metformin

• Indication: Traditionally a first-line defense against Type 2 diabetes
• Geroscience relevance: Inhibits Mitochondrial Complex I and activates AMPK (a metabolic master switch), which reduces oxidative stress, mimics the life-extending effects of caloric restriction, improves insulin sensitivity, and reduces inflammation [6]
• Evidence: Observational studies suggest reduced mortality in diabetics; supported by the Diabetes Prevention Program [7]

 
Rapamycin (Sirolimus)

• Indication: Originally an immunosuppressant for organ transplants
• Geroscience relevance: Inhibits the mTOR pathway, triggering autophagy, the body’s cellular "recycling" system that clears out damaged proteins, and extends life span. Rapamycin is the most contoversial among gerotherapeutics. Despite the high level of enthusiasm in the longevity community, mainstream medicine remains cautious considering side effects like immunosuppression and lipid abnormalities
• Evidence: Robust lifespan extension in multiple animal species [8].

 
Acarbose

• Indication: Type 2 diabetes
• Geroscience relevance: An alpha-glucosidase inhibitor used to manage blood sugar spikes. By delaying carbohydrate absorption, it modulates IGF-1 signaling and shifts the gut microbiome toward producing beneficial short-chain fatty acids (SCFAs), effectively slowing the biological clock
• Evidence: Extends lifespan in mice, particularly males [9]

 
SGLT2 Inhibitors (e.g., Empagliflozin, Canagliflozin)

• Indication: Type 2 diabetes, heart failure, chronic kidney disease
• Geroscience relevance: These drugs help the kidneys clear glucose via urine. Beyond blood sugar, they seem to mimic the effects of caloric restriction and have shown significant lifespan extension in the National Institute on Aging’s Interventions Testing Program (ITP) in mice.
• Evidence: Large, randomized trials show that SGLT2 inhibitors reduced mortality and they are increasingly recognized for their "organ-protective" effects on the heart and kidneys, which are primary drivers of age-related decline [10,11].

 
GLP-1 Receptor Agonists (e.g., Semaglutide, Tirzepatide)

• Indication: Type 2 diabetes, weight management
• Geroscience relevance: These drugs mimic caloric restriction by suppressing appetite, increasing insulin secretion while suppressing glucagon release and slowing digestion. The overall effect is an increase in both health and life span demonstrated experimentally and clinically [12]
• Evidence: Cardiovascular outcome trials demonstrate reduced major adverse events [13]

 
Bisphosphonates (e.g. Alendronate, Zoledronate)

• Indication: Osteoporosis
• Geroscience relevance: They are drugs normally taken by senior citizens for brittle bones but surprisingly might have an anti aging effects. They exert these anti aging effects by inducing apoptosis in senescent cells and reducing inflammation. They improve mitochondrial structure and function and reduce muscle decline associated with aging. In animal studies, these drugs shifted the cellular composition of tissues toward those of younger counterparts [14,15].
• Evidence: Observational studies suggest reduced mortality independent of fracture prevention, with lower incidence of cancer and cardiovascular issues in patients using these drugs [16].